Erratum: Improved survival with bevacizumab in advanced cervical cancer (The New England Journal of Medicine (2014) 370 (734-743) DOI: 10.1056/NEJMoa1309748);Improved survival with bevacizumab in advanced cervical cancer

New England Journal of Medicine

Volumn 370, Issue 8, 2014, Pages 734-743

  Tewari, Krishnansu S ^a   Sill, Michael W ^b   Long III, Harry J ^c   Penson, Richard T ^d   Huang, Helen ^b   Ramondetta, Lois M ^e   Landrum, Lisa M ^f   Oaknin, Ana ^g   Reid, Thomas J ^h   Leitao, Mario M ⁱ   Michael, Helen E ^j   Monk, Bradley J ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c MAYO CLINIC   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF OKLAHOMA   (United States)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF ARIZONA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; PACLITAXEL; TOPOTECAN;

ADVANCED CANCER; ARTICLE; BLEEDING; CANCER RECURRENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIGESTIVE SYSTEM FISTULA; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MEDICAL HISTORY; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE; UTERINE CERVIX CANCER;

EID: 84894207820     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMx170002     Document Type: Erratum

References (38)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Tewari KS, Monk BJ. Invasive cervical cancer. In: DiSaia PJ, Creasman WT, eds. Clinical gynecologic oncology. 8th ed. Philadelphia: Mosby, 2012.
3. Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol 2007;25:2952-65. (Pubitemid 47123160)
4. Tewari KS. Expert panel: patients with metastatic/recurrent cervical cancer should be treated with cisplatin plus paclitaxel. Clin Ovarian Cancer 2011;4:90-3.
5. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649-55.
6. Tewari KS. A critical need for reappraisal of therapeutic options for women with metastatic and recurrent cervical carcinoma: commentary on Gynecologic Oncology Group protocol 204. Am J Hematol Oncol 2010;9:31-4.
7. Tewari KS, Monk BJ. The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma. Clin Adv Hematol Oncol 2010;8:108-15.
8. Tewari KS, Monk BJ. Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep 2005;7:419-34. (Pubitemid 41684228)
9. Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1985;3:1079-85. (Pubitemid 15004828)
10. Thigpen JT, Blessing JA, DiSaia PJ, Fowler WC Jr, Hatch KD. A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989;32:198-202. (Pubitemid 19041962)
11. McGuire WP III, Arseneau J, Blessing JA, et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 1989;7:1462-8.
12. Omura GA, Blessing JA, Vaccarello L, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1997; 15:165-71. (Pubitemid 27020569)
13. Bloss JD, Blessing JA, Behrens BC, et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2002;20:1832-7. (Pubitemid 34273273)
14. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2004;22:3113-9. (Pubitemid 41103724)
15. Long HJ III, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 2005; 23:4626-33. (Pubitemid 46224065)
16. Moore DH, Tian C, Monk BJ, Long HJ, Omura GA, Bloss JD. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010;116:44-9.
17. Tewari KS, Monk BJ. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. Semin Oncol 2009;36:170-80.
18. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9. (Pubitemid 20066716)
19. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:1069-74.
20. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400. (Pubitemid 38618122)
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
22. Cella DF. Manual for the Functional Assessment of Cancer Therapy (FACT) measurement system (version 4). Chicago: Northwestern University, Center for Outcomes, Research and Education (CORE), 1997.
23. Common Terminology Criteria for Adverse Events (CTCAE), v3.0. Bethesda, MD: Cancer Therapy Evaluation Program, 2006 (http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/ctc.htm#ctc-30).
24. Common Terminology Criteria for Adverse Events (CTCAE). v4.0. Bethesda, MD: Cancer Therapy Evaluation Program, 2011 (http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/ctc.htm#ctc-40).
25. Tewari KS, Monk BJ. Beyond platinum for metastatic and recurrent carcinoma of the cervix. Onkologie 2009;32:552-4.
26. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
27. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-220.
28. Wieand S, Schroeder G, O'Fallon JR. Stopping when the experimental regimen does not appear to help. Stat Med 1994;13:1453-8. (Pubitemid 24236197)
29. Lan KK, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
30. Diggle P, Liang KY, Zeger SL. Analysis of longitudinal data. Oxford, United Kingdom: Clarendon Press, 1993.
31. Bahadori HR, Green MR, Catapano CV. Synergistic interaction between topotecan and microtubule-interfering agents. Cancer Chemother Pharmacol 2001;48:188-96. (Pubitemid 32758892)
32. Tiersten AD, Selleck MJ, Hershman DL, et al. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol 2004;92:635-8. (Pubitemid 38183155)
33. No JH, Jo H, Kim SH, et al. Expression of vascular endothelial growth factor and hypoxia inducible factor-1alpha in cervical neoplasia. Ann N Y Acad Sci 2009; 1171:105-10.
34. Tang X, Zhang Q, Nishitani J, Brown J, Shi S, Le AD. Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin Cancer Res 2007;13:2568-76. (Pubitemid 46795128)
35. Tewari KS, Taylor JA, Liao SY, et al. Development and assessment of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model. Gynecol Oncol 2000;77:137-48. (Pubitemid 30217317)
36. Clere N, Bermont L, Fauconnet S, et al. The human papillomavirus type 18 E6 oncoprotein induces vascular endothelial growth factor 121 (VEGF121) transcription from the promoter through a p53-independent mechanism. Exp Cell Res 2007;313:3239-50. (Pubitemid 47284068)
37. Bodily JM, Mehta KP, Laimins LA. Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases. Cancer Res 2011;71:1187-95.
38. Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2010;28:3562-9.